• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Schrodinger Inc (NQ: SDGR )

    17.59 +0.02 (+0.09%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Schrodinger Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Schrödinger to Announce Third Quarter 2024 Financial Results on November 12
    From Schrödinger
    Via Business Wire
    Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
    From Schrödinger
    Via Business Wire
    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Schrödinger
    Via Business Wire
    What Analysts Are Saying About Schrodinger Stock
    Via Benzinga
    Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium
    From Schrödinger
    Via Business Wire
    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Schrödinger
    Via Business Wire
    AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
    Via Talk Markets
    AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
    Via Talk Markets
    Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
    The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
    Via Talk Markets
    Topics Economy
    Exposures Economy
    Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
    Via Talk Markets
    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Schrödinger
    Via Business Wire
    AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
    The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
    Via Talk Markets
    Schrödinger to Present at Morgan Stanley Global Healthcare Conference
    From Schrödinger
    Via Business Wire
    The 3 Best Med Tech Stocks to Buy Now
    Med tech firms are tremendously improving healthcare and making a great deal of money. Here are the three best med tech stocks to buy now. 
    Via InvestorPlace
    SDGR Stock Earnings: Schrodinger Beats EPS, Beats Revenue for Q2 2024
    SDGR stock results show that Schrodinger beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Schrödinger Reports Strong Second Quarter 2024 Financial Results
    From Schrödinger
    Via Business Wire
    AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
    The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
    Via Talk Markets
    3 Small-Cap Stocks to Buy at a 52-Week Low
    The Russell 2000 is hinting at sector rotation, meaning it’s time for bargain hunters to look for small-cap stocks at 52-week lows 
    Via InvestorPlace
    Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology
    From Schrödinger
    Via Business Wire
    3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts
    The Fed is widely expected to cut interest rates a great deal. Here are three stocks to buy to benefit from these interest rate cuts. 
    Via InvestorPlace
    Topics Economy
    Exposures Interest Rates
    AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
    To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
    Via Talk Markets
    Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
    From Schrödinger
    Via Business Wire
    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Schrödinger
    Via Business Wire
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
    Via Talk Markets
    Simulations Plus Stock Drops 15% Despite EPS Beat
    Simulations Plus fell 15% the day after its earnings release despite beating EPS estimates due to lower margins and lower full-year guidance. 
    Via MarketBeat
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    3 Top-Rated Gene Editing Stocks Actually Making Money
    Profitable gene editing stocks make increasingly compelling investments as therapies commercialize this year and beyond. 
    Via InvestorPlace
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
    Via Talk Markets
    AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
    The global 
    Via Talk Markets
    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Schrödinger
    Via Business Wire
    AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
    The global 
    Via Talk Markets
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.